The HBP Pathway Inhibitor FR054 Enhances Temozolomide Sensitivity in Glioblastoma Cells by Promoting Ferroptosis and Inhibiting O‐ GlcNAcylation
CNS Neuroscience & Therapeutics · 2025
DOI: 10.1111/cns.70546 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2025. Verfasst von Rongxu Ye und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China. Hauptthemen laut MEDLINE: Glioblastoma, Ferroptosis, Temozolomide, Brain Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Guangdong Provincial Department of Science and Technology, Clinical Research Fund of Nanfang Hospital, Southern Medical University.
Abstract (Originalsprache)
Background
The clinical efficacy of temozolomide (TMZ) in glioblastoma (GBM) patients is often limited by the development of resistance. To date, no clinically validated therapeutic strategies exist to restore sensitivity to TMZ treatment. In this study, we investigated the potential of FR054, a hexosamine biosynthesis pathway (HBP) inhibitor, to sensitize GBM cells to TMZ and elucidated its underlying molecular mechanism.
Methods
TMZ‐resistant U87‐MG and A172 cell lines were generated through stepwise exposure to increasing concentrations of TMZ. Proteomics and bioinformatics analyses revealed HBP activation in these resistant cells. The effects of FR054 alone or in combination with TMZ were assessed using cell line models, GBM organoid models, and intracranial xenograft models. Transcriptomic analysis and validation experiments were further conducted to explore the molecular mechanisms involved.
Results
Long‐term exposure to TMZ induced resistance in U87‐MG and A172 GBM cells, which was associated with the activation of the HBP pathway. PGM3, a key enzyme in the HBP, was found to correlate with poor prognosis in GBM patients. The combination of FR054, a specific PGM3 inhibitor, with TMZ exhibited synergistic inhibitory effects in vitro and superior inhibitory efficacy in GBM organoid models. In vivo, this combination significantly suppressed tumor progression and prolonged survival in orthotopic xenograft mice with minimal side effects. Mechanistically, FR054 enhanced TMZ sensitivity by inhibiting protein O‐GlcNAcylation and promoting ferroptosis via the upregulation of HMOX1 and downregulation of GPX4.
Conclusion
Our findings demonstrate that targeting the HBP pathway with FR054 can overcome TMZ resistance in GBM by reducing O‐GlcNAc modification and inducing ferroptosis. This novel approach enhances the efficacy of TMZ, offering a promising therapeutic strategy for GBM patients with limited treatment options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
- The Laboratory for Precision Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
- The First Clinical Medical College, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
- School of Public Health, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
- Nanfang Glioma Center, Guangzhou, Guangdong, People's Republic of China.
- Institute of Brain Disease, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
ORCID-Profile: Shanqiang Qu, Junyi Xu, Guanglong Huang, Guo-Zhong Yi
Förderung
- National Natural Science Foundation of China
- Guangdong Provincial Department of Science and Technology
- Clinical Research Fund of Nanfang Hospital, Southern Medical University
- Research Fund of Nanfang Hospital, Southern Medical University
Zitieren
APA
Ye, R., Zhang, W., Zhang, H., Qu, S., Xu, J., Xu, R., Zhu, Y., Huang, G., Zhang, X. A., & Yi, G. Z. (2025). The HBP Pathway Inhibitor FR054 Enhances Temozolomide Sensitivity in Glioblastoma Cells by Promoting Ferroptosis and Inhibiting O‐ GlcNAcylation. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70546
Vancouver
Ye R, Zhang W, Zhang H, Qu S, Xu J, Xu R, et al. The HBP Pathway Inhibitor FR054 Enhances Temozolomide Sensitivity in Glioblastoma Cells by Promoting Ferroptosis and Inhibiting O‐ GlcNAcylation. CNS Neuroscience & Therapeutics. 2025. doi:10.1111/cns.70546
BibTeX
@article{Ye2025,
author = {Ye, Rongxu and Zhang, Wanghao and Zhang, Huayang and Qu, Shanqiang and Xu, Junyi and Xu, Rongyang and Zhu, Ye and Huang, Guanglong and Zhang, Xi-An and Yi, Guo-Zhong},
title = {The HBP Pathway Inhibitor FR054 Enhances Temozolomide Sensitivity in Glioblastoma Cells by Promoting Ferroptosis and Inhibiting O‐ GlcNAcylation},
journal = {CNS Neuroscience & Therapeutics},
year = {2025},
doi = {10.1111/cns.70546}
}
EUVIMED